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Abstract
Melanoma is one of the most aggressive forms of skin cancer, and is very difficult to treat as 
resistance to existing treatments almost invariably develops. The disease is genetically heterogenous
which further increases the challenges of developing new treatments against it. Exploring how 
differing levels of different proteins affect the tumor cells is the key in identifying new targets for 
future treatments. 
MITF is the master transcription factor of melanocytes, and is shown to be able to control a large 
portion of the melanocyte genome. While it is only directly mutated in about 20% of melanomas, it 
is directly or indirectly deregulated in most patients. This, combined with the MITF-m-isoform of 
the protein having melanocyte-specific expression, makes the gene interesting as potential future 
drug target against melanoma. Increased knowledge about its targets and its effect on gene 
expression would provide valuable insights. Here, we demonstrate the effects MITF downregulation
have on the tumor suppressor genes AP-2a and AP-2c, the membrane bound growth factor receptors
ERBB2 and ERBB3, and the intracellular signaling proteins AKT and ERK. To compare samples, 
siRNA-mediated gene knockdown in SK-Mel28 melanoma cells was performed by using the 
transfection methods Photochemical Internalization and Lipofectamine 2000. Photochemical 
Internalization was shown to significantly affect MITF levels and was abandoned in favor of 
Lipofectamine 2000 transfection. Knockdown of MITF was shown to reduce levels of AP-2a 
significantly, while increasing levels of ERBB3. These effects were consistent at both a protein 
level and RNA level. Furthermore, reduced levels of MITF resulted in increased signaling in the 
PI3K/AKT-pathway, a pathway that also has been previously shown to be regulated by ERBB3. 
Lowered levels of AP-2a was found to reduce AKT-signaling. The MAPK/ERK-pathway was also 
examined, but no change was observed after either MITF or AP-2a siRNA knockdown. MTS assay 
experiments showed an increase in metabolic activity in cells transfected with MITF siRNA. These 
results indicate that MITF regulate genes capable of both assisting and preventing melanoma 
progression.
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1 - Introduction
1.1 Cancer
Cancer is a group of diseases caused by abnormalities in the cells of the body, causing cell growth 
to be deregulated, and later grants the cells the ability to spread to different parts of the body. Most 
types of cancers initially form a concentrated mass of cells, known as a tumor. The cells continue to 
grow uncontrollably and attain the ability to spread to other locations of the body, forming new 
tumors. If left untreated, the uncontrolled growth of cancer cells will cause displacement and 
damage of surrounding tissue and organs, eventually leading to the death of the diseased individual.
Carcinogenesis, the process in which a normal cell transforms into a cancer cell, is when a cell 
undergoes multiple genetic and/or epigenetic changes. These changes generally offer proliferative 
advantages to the cell. In 2000, Hanahan and Weinberg proposed six hallmarks that would define a 
cancer cell [1]: autonomy from growth signals, evasion of growth inhibitory signals, resistance to 
death by apoptosis, unlimited replicative potential, the ability to cause angiogenesis, and the ability 
to invade other tissues and metastasize. In 2011, they updated this list with four more hallmarks [2]:
genome instability, tumor-promoting inflammation, the ability to reprogram metabolism, and 
evasion of destruction by the immune system. (figure 1) 
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Figure 1: The hallmarks of cancer, as presented by Hanahan and Weinberg in 2011. Mutations contributing to one of
these attributes are essential for carcinogenesis [2].
There are two broad types of genes that are mutated in mutagenesis: proto-oncogenes and tumor 
suppressor genes. Proto-oncogenes are generally genes that drive cell proliferation, growth and 
division, and acquire mutations that increase their activity by either increasing the quantity of said 
gene, or through a functional change that makes the gene more active. Tumor suppressor genes, on 
the other hand, prevent cell proliferation, and acquire mutations that decrease their activity either 
partially or completely. 
There are many physical and chemical agents that can potentially initiate the development of 
cancer. Most of these agents, commonly known as carcinogens, work by inducing DNA damage in 
cells. Examples of this include chemical compounds that bind to or react with DNA, and high-
frequency electromagnetic radiation. Common for these carcinogens is that they induce breaks in 
the DNA strands, and damages the bases that make up the DNA code [3]. Ultraviolet radiation can 
cause damages by creating pyrimidine dimers, which causes the DNA to be unreadable by the 
proteins that attempt to access the genetic code [4, 5]. Chemicals that bind to DNA can make the 
process of replication more prone to errors [6, 7].  Certain viruses can also function as carcinogens, 
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by shutting down genes important for regulating cell division [8].
The cells in the human body do have mechanisms to repair the vast majority of the damages 
induced by carcinogens. However, over time DNA damages will still have a chance to accumulate 
and will generally pose an increased risk for cancer development later in life.
As cancer is a disease derived from the cells in the body rather than an external infectious agent, 
treatment of cancer can be challenging, and often induce severe side-effects. Common ways to treat 
diagnosed cancers involve surgery to remove tumors, use of chemical compounds that kill fast-
growing cells (chemotherapy) and radiation therapy where tumors are irradiated by gamma 
radiation. Another strategy that is becoming more common is to use medication that primarily affect
cells with specific mutations, known as personalized cancer therapy [9-12].  Much of the current 
research on cancer aimed at finding potential targets for such therapy, as well as developing 
medication against specific targets [8].
Cancer is one of the most common causes of death in the developed world. In Norway there were 
29 907 new cases of cancer registered in 2011, as well as 10 970 deaths caused by cancer in the 
same year [13]. On a worldwide basis, it accounts for roughly one in eight of all deaths. As such, 
cancer is very much a relevant research topic; increased understanding of the molecular processes 
that underlies cancer has the potential to save many lives, as well as increasing our overall 
understanding of how living cells function.
1.2 - Melanoma
Melanoma is a form of cancer derived from the pigment-producing cells known as melanocytes. 
Melanocytes are found in the skin, but also in the eye and the colon. Melanoma can occur in any 
region where melanocytes are present, but the disease is primarily known as a skin cancer. The 
neoplasm usually takes the form of an irregular, growing mole on the skin. The neoplasm has three 
sequential growth phases: radial growth phase(RGP), vertical growth phase(VGP) and the 
metastatic phase. During the radial growth phase, the tumor expands without penetrating deeper 
into the skin layer; the vertical growth phase involves growth deeper into the skin layers, and during
the metastatic phase the cancer spreads to other sites in the body [14].
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Melanoma is a very aggressive form of cancer, and is considered the most lethal type of skin cancer,
accounting for less than 2 % of total skin cancer cases. While being responsible for approximately 
75% of all skin cancer related deaths. One of the risk factors most commonly associated with 
melanoma development is exposure to ultraviolet (UV) radiation. UV radiation can induce DNA 
damage [4], and cells in the skin are commonly exposed to UV radiation from the sun. Melanocytes
function as a defense mechanism against this: they produce the pigment known as melanin, which 
absorbs portions of the damaging radiation before it can cause harm in the body. The incidence of 
melanoma is thereforehigher in fair-skinned individuals than dark-skinned individuals, as their 
lower levels of melanine makes them more susceptible to UV-induced DNA damage [15]. 
Individuals that have been frequently sunburned in the past are also at a higher risk than the general 
population.. Melanoma has become more common in Norway today compared to the 1950s, an 
increase that has been linked to changes in UV exposure and the use of tanning beds. In 2012 a total
of 1755 new cases of melanoma were registered in Norway[13].
If identified before metastasis surgical removal of the tumor is an effective treatment that reduces 
the possibility of recurrence in most patients. However, if the melanoma has spread, the survival 
rate of patients greatly decreases. Melanoma has a high level of heterogeneity, which makes it more 
complicated to develop single treatments that can cover for all melanoma subtypes. [20] Treatments
against metastatic melanoma include; chemotherapy, radiation therapy, and immunotherapy (Table 
1). Traditionally, the alkylating agent Dacarbazine (DTIC) has been used to treat advanced 
melanoma, but the drug has a low response rate (7-13%) [17-19] and has severe side-effects. In 
recent years, multiple targeted therapies have been developed and approved for melanoma 
treatment. [21] Of particular note here is Vemurafenib, a kinase inhibitor specific for BRAF with a 
V600E-mutation. The drug has been approved by the FDA in the United States, and shows good 
initial response rate against advanced melanoma with a BRAF(V600E)-mutation. Unfortunately, the
cancer almost invariably develops resistance towards the drug when administered as the sole 
treatment [4-6], but Vemurafenib shows great promise when administered together with other drugs 
as a combination therapy. [21] 
Immunotherapy, a modality designed to direct the immune system towards the cancer cells, is also 
showing great potential for treatment of melanoma, and the effects therapeutic antibodies on 
13
advanced melanoma is a promising field of research. Of particular note are Ipilimumab and 
Nivolumab: the former is an antibody that blocks the CTLA-4-receptor on the surface on T-cells, 
which initiates an immune response against tumor cells. [22, 23]  Nivolumab functions by binding 
to the PD-1 receptor of the melanoma cells, directing the immune system to those cells. Both sets of
treatments have individually been shown to increase survival rates amongst patients.  [17, 23] 
However, a combination of the two drugs has shown far greater response rates than each drug 
administered alone, and a Ipilimumab-Nivolumab-combination therapy has been suggested as a 
potential treatment for the future. [24, 25] Table 1 outlines several drugs used against melanoma, as 
well as their targets.
Treatment Target of inhibition Reference
Imatinib c-KIT [26]
Vemurafenib BRAF(V600E) [21, 22, 27] 
Interleukin-2 (IL-2) IL-2 receptor [28]
CDK Inhibitors Cyclin Dependent Kinases [27, 29]
Sorafenib BRAF [21]
Rapamycin mTOR [30]
Nivolumab PD-1 [17, 21, 24, 25]  
Ipilimumab CTLA-4 [21-25, 31]  
Dabrafenib BRAF [20, 21] 
 Table 1: Melanoma treatments and their targets
1.3 - Personalized cancer therapy
In recent years, changes have happened in the approach to cancer research and treatment. It is 
difficult to predict patient prognosis based on the anatomical origin of the tumor. Also, while 
traditional treatments like chemotherapy and radiotherapy have proven effective, they also come 
with serious side effects. The doctrine of "personalized cancer therapy" has therefore gained 
significant popularity. The idea that identifying the phenotypes of individual patients, and picking a 
treatment specifically for the mutations the tumors in the patient has acquired, is potentially more 
effective method than attempting to use a catch-all treatment. As genetic sequencing is becoming 
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cheaper and faster, and more drugs targeting specific proteins are being developed, this method is 
becoming more and more feasible, as mutations can be identified and treatments can be tailored 
specifically for the patient. The advances in sequencing and expression assay technology allow 
individual tumors to be analyzed for specific mutations, providing valuable information that can 
help inform on the effectiveness of different treatments. This ability to identify mutations greatly 
increases the value of treatments targeting genes that may not always be mutated. 
One of the most common examples of a success story in personalized cancer therapy is 
Vemurafenib. Developed by Plexxicon and approved by the FDA in 2011, it is a kinase inhibitor 
specific for BRAF with a valine-glutamine substitution at the amino acid side chain valine-600 [21, 
22, 27]. This specific mutation is common in melanoma and results in constant proliferative 
signaling, and for that reason vemurafenib is commonly used to treat melanoma patients with 
tumors positive for BRAF(V600E). Initial response rates are high, and as the inhibitor is specific for
the mutated BRAF, the side-effects are mild in comparison to chemotherapeutic agents like DTIC 
[11]. However, resistance to the drug invariably develops after a few months, and disease relapse is 
very common [11, 21, 27]. It has been shown that combining Vemurafenib with another target-
specific drug greatly reduces the risk of tumor cells developing drug resistance [27]. The goal is to 
discover new drug that targets will give more tools in the fight against cancer and be less straining 
on the patients compared to current therapies. For this reason, an important focus of cancer research
is examining the potential of new genes as cancer drug targets.
An ideal drug target is a gene that is important for cancer development, can be easily targeted, is 
commonly found in the cells, and causes less severe side effects in the patient compared to other 
treatments. BRAF(V600E) is a prime example of a gene exhibiting all of these attributes [101]. 
Determining genes with similarly suitable properties could improve chances of finding future 
treatment methods.
1.4 - Signaling pathways in melanoma
Alteration of the signaling pathways in a cell is an essential part of carcinogenesis. For a cell to 
become cancerous, it is necessary to deregulate pathways that control cell growth, metabolism, 
apoptosis and gene repair, in ways that favor proliferation and cell division [32]. In melanoma, the 
pathways that are the most relevant for disease progression include the MAPK-pathway, the 
PI3K/AKT-pathway, the Wnt/B-catenin-pathway and A-MSH-pathway [33]. Table 2 outlines some 
of the most common genetic changes found in melanoma.
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Mutation Incidence Reference
BRAF(V600E) ~50% [34]
NRAS 15-25% [35]
MITF amplification 21% [36]
p53 13% [33]
p21 30-40% [33]
Table 2: Common mutations in melanoma
One of the greatest challenges with melanoma treatment is how resistance towards drugs often 
arise. Identifying mechanisms behind how resistance develops is therefore important in improving 
patient survivability. Increased signaling in the PI3K/Akt-pathway and the MAPK/ERK-pathway 
are often found in cells that have been treated with BRAF(V600E)-inhibitors and developed 
resistance to them [37-39]. This highlights the importance of these pathways for cancer cell 
survival. The microphthalamia-associated transcription factor (MITF) is one of the most important 
transcription factors in melanocytes [36, 40], and has shown to be linked to BRAF(V600E)-
resistance [77], as well as being able to influence both the PI3K/AKT- and MAPK/ERK-pathways 
[62, 77, 78]. Increased insight in how MITF is linked to these pathways could provide valuable 
knowledge in how to combat melanoma.
1.5 - Microphthalmia-Associated Transcription Factor (MITF)
The Microphthalmia-Associated Transcription Factor is a 52kDa basic Helix-loop-helix 
transcription factor that acts as the master regulator of melanocyte development. [36, 40] It belongs 
to the MiT-family of transcription factor proteins, along with Transcription Factor E Box-proteins 
TFEB, TFEB3 and TFEC [16, 41]. These proteins are capable of forming homodimers and 
heterodimers involving other proteins from the MiT-family, but not other bHLH-proteins [42]. 
There are nine isoforms of the protein. The isoform MITF-M has melanocyte-specific expression 
(figure 2) [16, 36]. In a hetero- or homodimeric form, MITF is capable of binding to a 10 base-pair 
motif known as the M-box, with the sequence of 5'-GTC ATG TGC T-3', and the E-box, with the 
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consensus sequence of 5'-CANNTG-3' [79].
Figure 2: the nine different isoforms of MITF. The melanocyte-specific MITF-M is the only splice variant that lacks the
b1b-part of exon 1, and instead has the 1m exon. All other isoforms have b1b plus an unique exon. Schematic diagram
based on Levy et al [36].
MITF levels are commonly altered in melanoma cells compared to healthy melanocytes. However, 
in comparison to many other genes relevant to cancer development, the MITF gene itself is 
relatively rarely mutated [43]. Several studies have found amplification of the MITF gene in about 
20% of melanoma tumors, as well as a relevant point mutation (E318K). Additionally, these studies 
have concluded that upstream regulators and the tumor microenvironment are more important 
factors in terms of regulating MITF levels than direct mutations are [43, 44]. Certain phenotypes of 
cancer cells are indicated to be correlated with different levels of MITF activity: low activity is 
associated with stemness; medium levels are associated with proliferation and invasion; high levels 
are associated with differentiation [45, 46].
MITF transcription is regulated by a multitude of pathways, some of which are shown in figure 3. 
Of particular note are the transcriptional promoting effects of Wnt, c-KIT, BRAF(V600E) and 
SOX10, all of which are commonly deregulated in melanoma [43, 47]. BRAF(V600E) is capable of
influencing multiple pathways that modulate MITF transcription, both as activators and 
suppressors. BRAF(V600E)-positive melanoma cells are associated with low levels of MITF, 
however [48].
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Figure 3: the effects of different pathways on MITF expression. Proteins shown in green function as enhancers of
expression, while proteins shown in red function as repressors. Adapted from a figure from Hartman et al [45].
Post-transcriptional regulation of MITF activity is achieved through regulation of transcript 
stability. The protein complex coding region determinant-binding protein (CRD-BP) helps 
stabilizing the mRNA. Several micro-RNAs are capable of binding to MITF mRNA, which 
promotes enzymatic breakdown of the transcript. The protein can also be phosphorylated at Ser-73 
and Ser-409, which both makes the protein transcriptionally active. Phospho-Ser-73 also flags 
MITF for degradation by the ubiquitin-proteasome pathway [43, 49]. Interestingly, c-KIT and 
BRAF(V600E) are indicated to take part in this phosphorylation, in addition to their transcription-
promoting effects on MITF, though they exert their effects indirectly rather than actively 
phosphorylating MITF themselves [48, 49].
MITF-m is capable of affecting genes involved in a vast array of functions, including 
differentiation, proliferation, senesence and migration [45]. The gene is important in melanocyte 
development, and is commonly altered directly or indirectly in melanoma. For these reasons, efforts
are being made to investigate the downstream targets of MITF, as well as its potential as a future 
therapeutic target. MITF-m having melanocyte-specific expression further increases the interest of 
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the gene, as it could make it possible to specifically target cells expressing this isoform. However, 
this is complicated by the complex expression model of MITF, as different melanoma cell 
phenotypes express different levels of MITF [45]. Thus, it is hard to predict the effects of targeting 
MITF, and certain papers have concluded that MITF itself may not be a druggable target, and 
suggests focusing on the targets of MITF, and its regulators [45, 102].
In-house data indicates that members the AP-2 family of transcription factors could possibly be 
affected by MITF levels, as well as members of the HER / ERBB-family. Members of the AP-2 
family have been noted as tumor suppressors [51-53], while ERBB-proteins function as 
extracellular receptors that relay extracellular growth signals to the cells [64, 66]. To attain further 
knowledge of the effects of MITF in melanoma cells, this project will explore the effect MITF has 
on members of these families.
1.6 - Activator Protein 2  (AP-2)
The activator protein 2(AP2)-family of 52 kDa basic helix-loop-helix transcription factors. The 
proteins in this family contain a highly conserved b-HLH-motif that binds GC-rich areas in DNA 
(figure 4) [50], and are capable of forming both homo- and heterodimers. Humans have 5 genes in 
the AP-2-family: AP-2a, AP-2b, AP-2c, AP-2d and AP-2e. 
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Figure 4: a representation of an AP-2a homodimer. The bHLH-domain is responsible for DNA binding and 
dimerization. Schematic diagram adapted from The  AP-2 family of transcription factors (Eckert et al 2005)
[50].
The structure of an AP-2 alpha monomer consists of the N-terminal transactivation domain [50] and
the C-terminal DNA binding domain which is also responsible for dimerization. The homodimer 
binds to the consensus sequence of 5'-GCCNNNGGC-'3 [51].  AP-2a is reported to have four 
isoforms (1a, 1b, 1c and 1d) , with 1a being the most expressed isoform, though the 1b and 1c 
isoforms are commonly upregulated in breast cancer cells [85].
In recent years, the importance of AP-2 alpha as a tumor suppressor has been increasingly well-
documented. The gene has been found to be widely downregulated and/or disrupted in all stages of 
melanoma, and a high ratio of cytoplasmic to nuclear localization of AP-2 alpha has been found to 
correlate with poor patient prognosis [52]. Additionally, AP-2 alpha knockdown has been 
demonstrated to reduce levels of other tumor suppressor genes [51, 53], and the up-regulation of 
genes associated with cell proliferation and disease progression [54, 55], The gene is also shown to 
cooperate with p53 in order to induce p21 expression [56, 92], an anti-proliferative kinase that 
regulates the activity of several key proteins in cell cycle progression [57]. Furthermore, AP-2a has 
been shown to be a positive regulator of the serine-threonine-phosphatase PP-2A A Alpha, a major 
serine-threonine phosphatase responsible for as much as 50% of the phosphatase activity in 
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eukaryotes [80]. Its importance in melanocytes is also highlighted by its reported co-localization 
with MITF at promoters for genes involved in pigment cell differentiation [83]. AP-2C is not as 
prominently reported on as a tumor suppressor gene in melanoma compared to AP-2a, but studies 
have shown that reduced levels of AP-2C contribute to melanoma tumor progression [81]. The gene
is also a regulator of extracellular matrix 1 (ECM1) which is over-expressed in melanoma cells 
[82].
Increased knowledge of how AP-2 transcription factors affects melanoma cells could therefore 
provide key insights in how to combat melanoma.
1.7 - ERBB3
ERBB3 (HER3) is a member of the human epidermal receptor family, a family of receptor tyrosine 
kinases, which also encompasses HER2 / ERRB2, Epidermal Growth Factor Receptor (EGFR) and 
HER4 / ERBB4 [58]. These cell surface receptors relay growth factor signals to the cell by 
activating several important pathways for cell proliferation, including the PI3K / AKT-pathway and 
the MAPK / ERK-pathway [59, 60]. The ERBB-family proteins have a similar structure consisting 
of three main domains: an extracellular ligand binding domain, a single hydrophobic 
transmembrane region, and an intracellular region containing a conserved tyrosine kinase domain. 
The receptors are activated by assembling into homo- or heterodimers of other members of the 
family upon binding of extracellular ligands, with the notable exception of ERBB2, which is unable
to bind any known ligand [61].
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Figure 5: Representation of ERBB2/ERBB3 heterodimer signaling. Based on a figure by Gala et al [62].
ERBB3 is unique in the ERBB-family: until recently, it was thought that this receptor was 
enzymatically inactive. Although research has shown that the protein has an ability to bind ATP and 
autophosphorylate [63], it is unable to phosphorylate other proteins. It requires heterodimerization 
with another ERBB-protein in order to relay extracellular signals, though it has also been shown to 
dimerize with non-ERBB-family proteins [64, 65]. For this reason, the protein has been neglected 
somewhat by researchers as a potential therapeutic target in comparison to ERBB2 and EGFR: both
of these have targeted therapies developed against them [61]. It has been shown that ERBB3-
ERBB2-heterodimers are the most active of the ERBB-dimers [66].
ERBB3 is commonly found to be upregulated in several cancers. The ERBB2/ERBB3-dimer is 
shown to be essential for tumor formation in breast cancer [67]. Blocking the dimerization of 
ERBB3 has thus been explored as a way to use it as a therapeutic target [68]. ERBB3 has been 
demonstrated to be upregulated in cells resistant to ERBB2- and EGFR-treatments [65, 69, 70]. and 
increased ERBB-activity is also implicated to be one of the mechanisms behind resistance towards 
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treatments with BRAF(V600E)-inhibitors [60]. All of these discoveries highlight the importance of 
attaining further knowledge about ERBB3.
1.8 - Aims of the project
• Obtain efficient gene silencing of MITF and AP-2a in a cultured melanoma cell line
• Investigate a possible correlation between MITF and AP-2 alpha expression
• Investigate the effects of MITF and AP-2 alpha gene silencing on AP-2 gamma, ERBB2 and
ERBB3 expression levels
• Investigate the effects of MITF and AP-2 alpha gene silencing on signaling in the 
PI3K/AKT-pathway and MAPK/ERK-pathway
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2 - Methods and materials
2. 1 - Cell culturing
The cell line used for the project was the metastatic melanoma cell line SK-Mel28. In-house data 
shows that this cell line has an amplification of the MITF gene, and high expression levels of MITF 
protein and mRNA. The cells were grown in Nunc EASYFlask 75 cm2 (Thermo Scientific) and 
were kept at 37 oC with 5% CO2, using RPMI-1640 medium (Sigma) supplemented with glutamax 
and fetal bovine serum (FBS).
Cells are stored in liquid nitrogen when not in use, to prevent genetic changes from accumulating in
the cells. While frozen, the cells were kept in growth medium supplemented with FBS and the 
cryoprotective agent dimethyl sulphoxide (DMSO), the latter to prevent ice crystal formation which
might damage the cells. When the cells were to be cultured, they were removed from the freezer and
thawed in a water bath at 37 oC. When thawed, the cells were added to the cell culturing flasks, and 
20 ml of RPMI-1640 growth medium was added to the flask. After 24 hours, when the cells had 
adhered to the surface of the flask bottom, the medium in the flask was changed to remove any 
traces of DMSO, which is otherwise toxic to the cells.
The cell flasks were inspected by microscope daily, and when the confluence in the flask was high 
enough, the cells were split by the use of trypsin (usually 3-5 days after the last splitting), and 
samples were transferred to 6-well cell growth plates. When the cell confluence in the wells had 
reached at least 60%, the plates were ready for transfection.
2.2 - Transfection
Transfection methods are used to introduce foreign oligonucleotides into cells. The types of 
oligonucleotides introduced are commonly used to affect the expression levels of a gene of interest. 
Introducing the mRNA of a particular gene into a cell can lead to transiently increased levels of the 
translated protein in the cell. Similarly, introducing oligonucleotides that interact with and/or disrupt
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the existing mRNAs in the cells can lead to transiently downregulated levels of the gene in 
question. Disruption of mRNA happens when the interfering RNA bind to the mRNA, forming 
double-stranded RNA molecules. The dsRNA-molecules are recognized and divided into short 
fragments by the enzyme Dicer. These fragments are degraded by the RISC-complex [71].
For a transfection technique to be effective, it needs to effectively facilitate the uptake of the 
oligonucleotides into the cytoplasm of the cells. This can be challenging, as the negatively charged 
lipid surface of the cell membrane will repel negatively charged oligonucleotides, and the 
hydrophobic inner of the lipid bilayer also acts as an effective barrier that prevents uptake of the 
hydrophilic lipids. The method used should as far as possible not indirectly affect gene expression 
by itself, and have low toxicity.
In this project, two transfection methods were used to introduce siRNAs targeting MITF-m and AP-
2a in an attempt to downregulate them.
The sequences of the siRNAs used were:
AP-2a sense: GCA-GUA-GCU-GAA-UUU-CUC-A55 
AP-2a antisense: UGA-GAA-AUU-CAG-CUA-CUG-C55 
and
MITF sense: GCA-GUA-CCU-UUC-UAC-CAC-U55 
MITF antisense: AGU-GGU-AGA-AAG-GUA-CUG-C55 
For each transfection done in this project, there were made at least three control samples in addition 
to the samples transfected with AP-2a siRNA and MITF-siRNA, shown in figure 6. The controls in 
the LF2000-transfected cells involved one set sample with LF2000 added, one sample with LF2000 
and negative control siRNA added, and one untreated sample. The PCI-transfected cells had one 
control with PEI, TPPS2a and 435 nm light treatment, one control with PEI, TPPS2a negative control 
siRNA and 435 nm light treatment, one control with only 435 nm light treatment, and one untreated 
control.
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Figure 6: Representation of the wells with plated cells in LF2000-transfected cells and PCI-transfected cells, respectively.
2.2.1 - Transfection: Photochemical Internalization (PCI)
Photochemical internalization is a transfection method where macromolecules are delivered into 
cells through disruption of the endocytic pathway. Macromolecules are taken up by the cells 
through endocytosis, and the endosomes are destroyed by use of photosensitizers: molecules that 
are excited by certain wavelength of electromagnetic radiation [72, 73]. These sensitizers are 
hydrophobic, and will therefore be prone to integrate themselves into the membranes of the cells. 
The RNA that is to be taken up by the cells is mixed with a positively charged complexing agent, 
which facilitates attraction to outer cell membranes. The outer cell membrane will then fold inwards
and form vesicles called endosomes that will contain the RNA and complexing agent. This process 
is called endocytosis. When the cells are exposed to electromagnetic radiation of the wavelength 
that excites the photosensitizers, the excitation will facilitate the generation of free radicals and 
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reactive oxygen species that will react with and damage local molecules. As the sensitizers are 
inserted into cell membranes, and thereby endosomes, the endosomes will be destroyed, and the 
contents of the vesicles will be released [74, 75].
The light-source used in the PCI is a LumiSource lamp (PCI Biotech), which delivers blue light at 
435 nm with a fluence rate of 5.1 mW/cm2. The photosensitizer used was disulfonatedmeso-
tetraphenylporphine(TPPS2a) and the transfection reagent was polyethylenimine (PEI).
The transfection procedure was done as follows:
1) Add 200 μl of RPMI-1640 medium to an eppendorf tube, and add 50 nMol of siRNA with 8 μl of
PEI. Mix gently and incubate at room temperature for 30 minutes.
2) After incubation, add 800 μl of medium mixed with photosensitizer(PS) to the tubes. The 
concentration of PS post mixing should be 0,5 μg/μl.
3) Remove the growth medium in the cells that are to be transfected, and add the medium with 
siRNA and PS to the wells containing the cells
4) Wrap the cells in tinfoil to protect them from light, and incubate them overnight at 37 degrees C 
at 5% CO2
5) After incubation, wash the cells three times with RPMI-1640 medium, and add 3 ml of RPMI-
1640 medium with FBS and GlutaMax. Incubate for 4 hours at 37 oC at 5% CO2
6) Expose the cells to monochromatic light from LumiSource lamp for 45 seconds
7) Incubate the cells for 24 or 72 hrs prior to harvesting for protein/and or total RNA
2.2.2 - Transfection: Lipofectamine 2000
Lipofection is a transfection method that uses positively charged lipids as a method to deliver 
nucleic acids into target cells. As mentioned earlier, one of the issues with delivering nucleic acids 
into cells is that the negatively charged nucleic acids will be repelled by the negatively charged 
outer lipid layer of the cell membrane, as well as being unable to pass through the hydrophobic lipid
bilayer. By complexing the nucleic acids with positively charged lipids, the complexes are capable 
of passing through the cell membrane and into the cells. The cationic lipid formations used in our 
experiments were Lipofectamine 2000 (Invitrogen).
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50 nMol of siRNA was complexed with 7,5 μl of Lipofectamine 2000 in 1 ml of pure RPMI-1640 
medium, and were incubated for 30 minutes in order for complexing to finish. This was afterwards 
added to the target cells, and left for 24, 48 or 72 hours before the cells were taken for harvesting.
2.3 - Cell harvesting and RNA extraction
In order to examine the effects of the transfection protocols on the cells, the contents of the cells 
have to be isolated for total RNA. RNA was extracted from lysed cells by use of GenElute RNA kit 
(Sigma Aldrich).  The procedure was done as follows:
1) The growth medium was removed from the cells, and the cells were washed three times with 
PBS
2) 650 ml lysis buffer with 0,1% mercaptoethanol was added to each well
3) The cell lysate was added to a filtration column
4) Centrifuge the columns for 2 minutes at 14.000 x g
5) Discard the column and measure the amount of filtrate. Add a volume of 70% ethanol to the 
filtrate. Mix by vortexing.
6) Up to 700 μl of filtrate-ethanol-mix was transferred to a binding column, and centrifuged at 
14.000 x g for 15 seconds. The filtrate was discarded. This step was repeated until all the lysate had 
been run through the column.
7) 500 μl of wash solution #1 was added to the column, and centrifuged at 14.000 x g for 15 
seconds. The column was moved to a new 2 ml collection tube, the filtrate was discarded.
8) 500 μl of wash solution #2 was added to the column, and centrifuged at 14.000 x g for 15 
seconds.  The filtrate was discarded. 
9) 500 μl of wash solution #2 was added to the column, and centrifuged at 14.000 x g for 2 minutes.
The filtrate was discarded.
10) The column was centrifuged an additional time at 14.000 x g to dry the column.
11) The column was moved to a new 2 ml collection tube. 50 μl of elution solution was added to the
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column, and the column was centrifuged for 1 minute at 14.000 x g. The filtrate was reapplied to 
the column with a pipette, and centrifuged for 1 minute.
12) The samples were measured for RNA concentration and purity by NanoDrop 2000 
Photospectrometer (Thermo Scientific) by measuring absorption of electromagnetical wavelengths 
of 260, 280 and 230 nm.
2.4 - RNA precipitation
If the RNA samples were not pure enough for further experimental usage, they were precipitated 
and resuspended in elution buffer to remove any impurities. This would decrease the total RNA 
yield in the samples, and was only done if the absorption ratio between 260 nm and 280 nm, as well
as 260 nm and 230 nm, was unsatisfactory. A higher ratio than 1.4 was considered good for both 
260/280 and 260/230.
The procedure was done as follows:
1) Move the elution buffer containing extracted RNA to an eppendorf tube, and add an amount of 
isopropanol equal to the volume of the elution buffer, and an amount of 3M Sodium Acetate (pH = 
5,2) equal to 1/10th of the original volume, to the tube. Incubate overnight at -20 degrees C
2) Spin the samples down at 13,000g/min at 4 oC for 40 minutes
3) Check if a pellet has formed in the tubes, then remove the supernatant, wash the samples with 
75% EtOH
4) Spin the samples down at 13,000g/min at 4 oC for 15 minutes
5) Remove the EtOH, leave the tubes open for 1-2 minutes for the remaining of the EtOH to 
evaporate
6) Resuspend the pellet in elution buffer, examine the RNA amount and purity as described in the 
RNA extraction paragraph
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2.5 - iScript cDNA synthesis
In order to measure and compare the concentration of mRNA in the samples, the samples would be 
subjected to reverse transcriptase cDNA synthesis. This process uses the enzyme reverse 
transcriptase to create double-stranded complementary DNA from single-stranded mRNA, making 
the samples more stable and, more importantly, sets the samples up for real-time PCR.
For cDNA synthesis, the iScript cDNA Synthesis kit provided by Qanta was used. The synthesis 
was run on a GeneAmp PCR System 9700 provided by PE Applied Biosystems.
Tubes were set up containing the following:
-1 μg of sample RNA 
- 4 μl of 5x iScript Mix
- 1 μl of iScript Reverse Transcriptase
- RNase-free water to make the total volume of the tube 20 μl
The tubes were then run for synthesis with a program of 5 minutes at 22 oC, 30 minutes at 42 oC, 5 
minutes at 85 oC before cooling down to 6 oC. The cDNA samples were diluted to a concentration of
10 ng/μl and were stored at 4 oC until further use.
2.6 - Real-Time Polymerase Chain Reaction (qPCR)
Real-time polymerase chain reaction is a procedure used for quantitative comparison of gene 
expression in multiple samples. The process works by making a solution of DNA, primers for the 
gene one wishes to examine, a heat-stable DNA polymerase, deoxynucleotides (dNTP) and a dye 
that binds to double-stranded nucleotide strands, and follows the following steps:
- heating up the samples for the DNA to denature
- cooling the samples down enough for primers to anneal to the sample, and for the heat-stable DNA
polymerase to create new double-stranded DNA
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These steps are repeated many times, doubling the amount of double-stranded DNA in the solution 
for every run. When a dye that binds double-stranded DNA is present in the sample, it is possible to 
measure the absorption of electromagnetic radiation at a certain wavelength in real time, and by 
comparing the growth of the absorption rate between wells, it is possible to see what samples have 
higher or lower levels of the genes of interest.
Two types of genes are examined in parallel here: the genes of interest for the experiments, and (at 
least) two housekeeping genes, which are genes that are required for basic cellular function. As the 
expression of these genes should be unaltered in all the samples, having similar levels of 
housekeeping genes between the samples serve to ensure that equal amounts of total cDNA have 
been added to each sample [76].
For Real-Time PCR, PerfeCta SYBR Green Supermix provided by Qanta was used for the sample 
solutions. The samples were put on 96 well plates and the plates were covered by optical tape, both 
provided by Bio-Rad. The runs were conducted on a CFX Connect Real Time System, provided by 
Bio-Rad.
1) make a master mix for each gene of interest containing 30 μl SYBR green supermix, 16,4 μl 
ddH2O, 1,8 μl of forward primer and 1,8 μl of reverse primer for each sample
2) transfer 50 μl of the master mix to tubes
3) add 10 μl of cDNA to the tubes, mix
4) add 25 μl of this mix to adjacent wells in a 96-well Bio-Rad optical plate, creating two parallels
5) cover the plate with optical tape 
6) measure the difference in changes in absorbance over time as the PCR process runs 
Run setup:
1 - 95,0 oC for 3:00
2 - 95,0 oC for 0:15
3 - 60,0 oC for 0:35
4 - return to step 2, repeat 39 times
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5 - 95,0 oC for 0:10
6 - 60,0 oC for 0:30
7 - Establishing Melt Curve: 60,0 oC for 0:08, increments of 0,5 oC for 0:08, up to 95,0 oC
8 - 4,0 oC for 0:20
END 
2.7 - Protein harvesting
In order to examine the changes the transfections would cause at protein levels in the cell, it was 
necessary to extract proteins from the cells. The procedure for this was done as follows:
1) Cells are washed three times with cold PBS
2) 1 ml of cold PBS is added to the cells. The cells are then suspended into the PBS by use of a 
scrape.
3) The contents of the well is transferred to a eppendorf tube and put on ice.
4) The eppendorf tubes are spun at 4 oC at 13,000 g x min for 15 minutes
5) The supernatant is removed, and the pelleted cells are put at -80  ͦC overnight or longer
6) When the cells are removed from the freezer, they are put on ice, and lysis buffer with a protease 
inhibitor (Complete Mini) and a phosphatase inhibitor (pSTOP) are added to the pellet immediately
7) The tubes are vortexed, put on ice for 15 minutes, and vortexed again afterwards
8) The content of the tubes are sonicated three times, for three seconds each
9) The tubes are centrifuged at 13.000 g x min for 15 minutes at 4 oC
10) The supernatant containing the protein is transferred to a new set of tubes. The pellet is 
discarded.
2.8 - Protein concentration measurement by BioRad assay
To measure the protein concentration in the samples containing the extracted protein, the BIO-RAD
Protein Assay was used. This assay uses a solution containing the dye Coomassie Brilliant Blue G-
250, which changes color when it binds to amino acid side chains in proteins. The samples are 
examined by WALLAC 1420 MULTILABEL COUNTER, which measures the sample absorption 
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at 595 nm. This absorption rate is compared to standard samples of a known concentration.
A total of 10 μl of ddH2O with a protein concentration of 0, 1, 2, 3, 4 and 5 μl is mixed with 100 μl 
of dye solution in the wells of a 96 well cell culturing plate. Three parallels of each protein 
concentration are made, and the average absorption of each of these is used to create the standard 
curve. Afterwards, two parallels of 10 μl of each unknown protein sample is applied to the plate and
mixed with 100 μl of dye solution. The absorption is subsequently measured.
2.9 - Western blot
Western blot is a very powerful technique used to compare the levels of protein in samples. It is 
done by denaturing the proteins in the samples of interest through reduction and heating, as well as 
adding sodium dodecyl sulfate (SDS) to the samples. SDS is a negatively charged detergent that 
helps denature the cells, as well as giving each protein in the sample approximately the same 
charge/size-ratio. The samples can then be separated by applying them to a polyacrylamide-gel and 
then using an electrical field to separate them. Since the size/charge-ratio of the proteins in the 
samples is approximately equal, the proteins will be separated primarily based on size. A protein 
standard with visible bands of known concentrations is also added to the gel, which makes it 
possible to locate where in the gel proteins of a certain size will be found. After gel electrophoresis, 
the proteins on the gel are transferred from the gel to a nylon membrane by the use of an electrical 
current (blotting). These proteins can then be visualized by exposing them to antibodies specific for 
the gene in question.
The polyacrylamide gels used in this project was NuPAGE Bis-Tris 4-12% gels (Life 
Technologies). The blotting apparatus used is an iBlot (Invitrogen), and the blotting stack used is 
iBlot (Life Technologies).
The procedure is done as follows:
1) 20-30 μg of protein are added to the tubes, along with 1 μl of reduction agent and 2,5 μl of a 
loading buffer. Total volume sample is adjusted to 10 μl by adding double-distilled water.
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2) Samples are put on a 70 oC heating block for 10 minutes to denature the proteins
3) Samples are spun down and put on ice
4) A polyacrylamide-gel mounted in a gel electrophoresis apparatus, and the apparatus is filled with 
1x MOPS, up to the point where it covers the wells in the gel. The wells are washed by the use of 
syringe filled with 1x MOPS.
5) ~10 μl of the samples are added to the individual wells of the gel, as well as 2,5 μl of a ladder 
solution in one of the wells.
6) Electrophoresis runs at 150V for 90 minutes, or as long as is necessary to achieve a good 
separation of the proteins
7) The membrane is removed from its container, the gel is put in a blotting device along with the 
nylon membrane, and the desired blotting program is allowed to run
The process of visualizing the proteins is as follows:
1) The membrane is put in a blocking solution (5% dry milk or 5% bovine serum albumin) for 60 
minutes with agitation, and is then washed briefly with 0,1% TBST.
2) The membrane is incubated with a primary antibody overnight at 4 oC with agitation. Specifics 
for the solutions of the antibody varies depending on the antibody
3)The next day, the membrane is washed with 0,1% TBST 3 times for 10 minutes each
4) After washing, the membrane is incubated with a secondary antibody for 60 minutes with 
agitation. Afterwards it is washed with TBST 3 times for 10 minutes.
5) The membrane is put in a G:BOX visualizing machine (Syngene) and is added a visualization 
solution(Thermo Scientific). The machine then visualizes the strength of the protein bands in the 
gel.
The specifications and condition for each primary and secondary antibody used for visualization is 
shown in the appendix.
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2.10 - MTS assay
To investigate whether knockdown of MITF and AP-2a had an effecton metabolism, the MTS assay
was used. The basis for the assay is the dye MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). It is yellow in its base state, but in the 
presence of  NADP(H)-dependent oxidoreductases it is reduced to formazan, which has a purple 
color and an absorbance peak at 490 nm. This assay can be used to measure the metabolism of the 
cells: a higher absorbance at 490 nm indicates a higher level of viable cells.
400 μl of MTS solution (20% of the volume of growth medium) was added to each well. The cells 
were packed in aluminium foil and incubated at 37 oC. They were later inspected for visible changes
in medium color. If changes were observed, the plates were analyzed in a WALLAC 1420 
MULTILABEL COUNTER for absorption at 490 nm.
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3 - Results
3.1 - PCI greatly affects MITF and AP-2a mRNA levels
Several transfection protocols have been established for delivery of siRNA-molecules into human 
cancer cell lines. Here, we investigated if transfection by PCI would provide an efficient method of 
siRNA-delivery in the melanoma cell line SK-Mel28. The protocol described in the materials and 
methods section has been optimized for the SK-Mel28 cell line by in-house personell, and was used
for this reason. The delivered siRNA was targeting MITF and AP-2a, as well as a scrambled 
sequence used as negative control, and MEK1 as a positive control (data for MEK1 not shown).
Investigation of the effects of the PCI-transfection on the SK-Mel28 cells were done by qPCR. The 
transfected cells were lysed and their RNA was purified and the RNA-levels were measured before 
cDNA was made from the samples. The cDNA was then used for qPCR analysis. Tubulin binding 
protein (TBP) and Large Ribosomal Protein (RPLPO) were used as control samples, and are not 
shown in the result. MEK1 was used as positive control in the earliest transfection attempts to 
ensure the efficiency of the protocol (results not shown).
Results are shown in figure 7. Transfecting cells with MITF siRNA was shown to reduce the levels 
of MITF mRNA in the cells comparison to the control samples (figure 7a), and the same effect was 
observed for AP-2a in cells transfected with AP-2a siRNA (figure 7b). In addition, the cells 
transfected with MITF siRNA would lead to reduced levels of AP-2a mRNA in comparison to the 
controls (figure 7b). This supports the hypothesis that MITF directly influences the levels of AP-2a 
in the cells.
Additionally, it was also clear that PCI as a transfection method had a significant effect on the levels
of MITF in the cells. Compared to the untreated samples, applying light to the cells would reduce 
MITF levels by ~50%, and treating the cells with both light and photosensitizer would further lower
MITF-levels by 60% as compared to the light-treated control samples. As such, it was decided to 
abandon PCI as the transfection method of choice for the remaining of the project.
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Figure 7: PCI-induced siRNA transfection after 24 h by Real-Time PCR. Controls are shown in black bars, samples
transfected with AP-2a siRNA in white and samples transfected with MITF siRNA in gray. Figure 7a) shows the MITF
levels after various treatments, 7b) show the levels of AP-2a mRNA. The untreated control sample was set as baseline
control. Bars are presented as the average of three individual experiments and error bars show standard deviation
between the samples.
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3.2 - Successful siRNA knockdown with LF2000 after 24 h
After deciding to abandon PCI as the transfection method of choice, Lipofectamine 2000 was 
elected to be tested and compared with PCI as a transfection method. The protocol listed in the 
Materials and Methods-section has been optimized for transfection of SK-Mel28 by in-house 
personell. As with PCI, the siRNAs used were targeting MITF and AP-2a, as well as a scrambled 
negative control RNA sequence.
The samples transfected with LF2000 were examined by qPCR. As with the PCI-transfected 
samples, the RNA from the transfected samples was collected, measured, and used for cDNA 
synthesis. Samples were collected after either 24 hours or 72 hours, to compare the efficiency of the
protocol at different intervals. TBP and RPLPO were used as controls and their are not shown.
Figure 7 and 8 show the results from samples that were harvested after 24 hours. The samples 
transfected with MITF siRNA were shown to have lowered levels of MITF and AP-2a (figure 7a), 
while cells transfected with AP-2a siRNA showed lowered levels of AP-2a (figure 7b). Compared to
the samples prepared with PCI, the control samples were much closer to the untreated baseline 
control for both MITF and AP-2a.
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Figure 8: LF2000-induced siRNA transfection after 24 h by Real-Time PCR. Controls are shown in black bars, samples
transfected with AP-2a siRNA in white and samples transfected with MITF siRNA in gray. Figure 8a) shows the MITF
levels after various treatments, 8b) show the levels of AP-2a mRNA. The untreated control sample was set as baseline
control. Bars are presented as the average of three individual experiments and error bars show standard deviation
between the samples.
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As successful MITF- and AP-2a knockdown had been demonstrated, the levels of AP-2C, ERBB2 
and ERBB3 in the same samples were examined. Figure 9 shows mRNA levels of AP-2C, ERBB2 
and ERBB3 in samples harvested 24 hours after transfection. Results show an upregulation of AP-
2C mRNA levels by approximately 40% in the samples transfected with MITF siRNA (figure 9a). 
Furthermore, ERBB3 mRNA levels were more than 2-fold upregulated in the samples transfected 
with MITF siRNA (figure 9c), while the ERBB2 levels were unchanged (figure 9b).
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Figure 9: LF2000-induced siRNA transfection after 24 h by Real-Time PCR. Controls are shown in black bars, samples
transfected with AP-2a siRNA in white and samples transfected with MITF siRNA in gray. Figure 9a) shows the AP-2C
levels after various treatments, 9b) show the levels of ERBB2 mRNA, 9c) show the levels of ERBB3 mRNA. The
untreated control sample was set as baseline control. Bars are presented as the average of three individual experiments
and error bars show standard deviation between the samples.
3.3 - MITF and AP-2a knockdown affects pAKT protein levels after 24 h
While effects on the RNA levels of the transfected cells showed clear effects on RNA-levels, these 
differences may not be as pronounced at the protein level. A slow rate of protein turnover for the 
examined proteins would mean any changes in mRNA levels would not immediately translate to 
reduced protein levels. Thus, it was deemed necessary to investigate how MITF- and AP-2a 
knockdown affected protein expression. Protein samples harvested from cells transfected with 
Lipofectamine 2000 were harvested after 24 hours and analyzed by western blot. The levels of AP-
2a, MITF and ERBB3 in transfected cells were compared to the control samples, and the loading 
was evaluated by using Histone 3 as a loading control.
The results of the western blot analysis is shown in figure 10. These results mirrored the results of 
the qPCR-results. Samples transfected with MITF siRNA had its levels of MITF and AP-2a greatly 
reduced in comparison to the control samples, and significantly increased levels of ERBB3. 
Samples transfected with AP-2a siRNA had very low levels of AP-2a in comparison to the controls, 
with ERBB3 and MITF unaffected by the AP-2a siRNA treatment.
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Figure 10: LF2000-induced siRNA transfection after 24 h by western blot. H3 was used as loading control.
One of the goals of this project was to examine the effects MITF has on proliferative signaling and 
survival signaling in melanoma cells. For this reason, the levels of AKT, ERK, pAKT and pERK in 
the transfected samples were also examined. AKT, ERK and pERK levels were unchanged in all 
samples. pAKT levels were elevated in MITF-transfected samples, and reduced in AP-2a 
transfected samples (figure 11). 
Figure 11: LF2000-induced siRNA transfection after 24 h by western blot. H3 was used as loading control.
3.4 - qPCR data from LF2000-transfected samples after 72 h
In the 24 h transfections, several interesting effects were observed after MITF and AP-2a siRNA 
knockdown, in particular the upregulation of pAKT and ERBB3. To investigate whether these 
effects were short lived, 72 h transfections were carried out and analysed for both protein and 
mRNA. The procedure used in the 72 h transfections was, aside from the transfection time, 
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otherwise equal to the 24 h transfections.
Figure 12 and 13 show the results from samples that were harvested after 72 hours. The results were
consistent with the samples that were harvested after 24 hours. Transfection with AP-2a siRNA 
resulted in reduced levels of AP-2a (figure 12b), transfection with MITF resulted in reduced levels 
of MITF (figure 12a), as well as reduced levels of AP-2a (figure 12b), and elevated levels of AP-2C 
and ERBB3 (figure 13). The effects of the siRNA on the target genes were less pronounced 
compared to the cells harvested 24 hours after transfection.
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Figure 12: LF2000-induced siRNA transfection after 72 h by Real-Time PCR. Controls are shown in black bars,
samples transfected with AP-2a siRNA in white and samples transfected with MITF siRNA in gray. Figure 12a) shows
the MITF levels after various treatments, 12b) show the levels of AP-2a mRNA. The untreated control sample was set as
baseline control. Bars are presented as the average of three individual experiments and error bars show standard
deviation between the samples.
As with the samples harvested after 24 h, the samples harvested after 72 h were examined for AP-
2C and ERBB3. The levels of ERBB3 saw a twofold increase in the MITF-transfected samples in 
comparison to the control samples. Similarly, the AP-2C levels in the MITF-transfected samples 
were increased by around 40%. No significant change was observed in neither ERBB3 nor AP-2C 
in the samples treated with AP-2a siRNA.
In the 24 h samples, ERBB2 mRNA levels had also been investigated by qPCR. In those samples, 
transfection did not have any observable effect on ERBB2-expression. This, combined with time 
constraints on the project, led us to abandon qPCR analysis of ERBB2 on the 72 h samples.
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Figure 13: LF2000-induced siRNA transfection after 72 h by Real-Time PCR. Controls are shown in black bars,
samples transfected with AP-2a siRNA in white and samples transfected with MITF siRNA in gray. Figure 13a) shows
the AP-2C levels after various treatments, 13b) show the levels of ERBB3 mRNA. The untreated control sample was set
as baseline control. Bars are presented as the average of three individual experiments and error bars show standard
deviation between the samples.
45
3.5 - Western blot analysis after 72 h
As with the qPCR-samples, the effects seen at a protein level after 24 h of LF2000-transfection 
showed several interesting effects, and it was decided to investigate whether the same effects would
be observed after 72 h of transfection. 
The results for the 72 h samples were consistent with the data obtained from the 24 h samples, and 
are shown in figure 14. MITF knockdown caused a very significant downregulation of MITF 
protein, caused a downregulation of AP-2a, and an upregulation of ERBB3 and pAKT, while AP-2a 
knockdown caused lowered levels of pAKT. The effect of the knock-down was not as pronounced 
in the 72 h  samples as in the 24 h samples.
Figure 14: Results of the western blot run for samples transfected with MITF and AP-2a siRNA. H3 was used as
loading control.
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3.5 - MITF knockdown increases metabolic activity in SK-Mel28 
The analysis of protein and mRNA levels in the transfected cells provide insights on how MITF and
AP-2a knockdown affect specific proteins and signaling pathways, but not on how it affects the cell 
as a whole. To gain insight on this, the MTS assay was used. As described in the Materials and 
Methods-section, the dye MTS was added to the wells of the plated cells, and analyzed for 490 nm 
absorption after 5 minutes. The dye changes color as the cells metabolize, thus it gives a method for
measuring metabolic activity: higher abs indicates increased activity.
Results of the MTS assay are shown in figure 15, with supplementary figures in Appendix D. The 
untreated cells had the consistently lowest abs. The MITF transfected cells had a higher abs. rate 
than the treated controls and the AP-2a transfected cells.
Figure 15: Relative absorption rate between transfected samples. Controls are shown in black bars, samples
transfected with AP-2a siRNA in white and samples transfected with MITF siRNA in gray. Control Untreated control
samples are set as baseline control. MITF transfected cells had the consistently highest abs. rates. Error bars show
standard deviation between the samples. Absolute numbers for the abs. rates are found Appendix D.
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4 - Discussion
4.1 - LF2000 is preferred over PCI as a transfection method for SK-Mel28
As stated in the introduction section, one of the goals of this project was to attain effective silencing
of MITF and AP-2a. To this end, two different transfection methods were employed at the 
beginning of the project: PCI and Lipofectamine 2000. When comparing qPCR-data from cells 
transfected with the two transfection methods, it is clear that LF2000 is preferred to PCI for 
transfection of SK-Mel28, at least when the goal is to study MITF and AP-2a. Both methods were 
efficient for siRNA knockdown. Interestingly, MITF knockdown also resulted in reduced levels of 
AP-2a compared to the control samples, indicating that MITF is a regulating modulator of AP-2a 
expression. However, when comparing mRNA levels of MITF and AP-2a in the control cells of the 
PCI-transfected cells (figure 7) and in the LF2000-transfected cells (figure 8), treating the cells with
435 nm light caused a significant drop in MITF mRNA levels, while LF2000 did affect MITF 
expression far less severely. MITF is considered one of the most important genes in melanocyte 
differentiation and function, and is also responsible for melanin production in melanocytes [40]. As 
MITF levels are affected by UV light [84], it is less surprising that treating melanoma cells with 435
nm light will have an effect on the expression levels of MITF present in the cell. The differences in 
AP-2a mRNA levels between the treated controls and the untreated control can be explained by the 
differences in MITF levels, as knock-down of MITF resulted in reduced levels of AP-2a.
As mentioned above, it has been documented that exposing melanocytes to ultraviolet (UV) 
radiation can affect MITF levels [84]. However, in other studies, UV-treatment has resulted in 
upregulation of MITF levels, rather than the effect observed in this project. UV-radiation has a 
shorter wavelength (400 nm - 100 nm) than the light used for transfection in this project (435), so 
the data from this project does not directly contradict previous studies. The observed change in 
MITF indicates that different wavelengths of electromagnetic radiation could have opposing effects 
on MITF levels.  Further experiments could verify this, and whether this is true for light of shorter 
wavelengths than what was used in this project as well.
The reagents used for transfection in PCI, PEI and TPPS2a, caused a greater change in MITF levels 
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compared to LF2000. MITF- and AP-2a levels were reduced by 15-30% in samples where LF2000 
was added when compared to untreated controls. Samples treated with light and photosensitizer 
were reduced by 70-80% in comparison to the light-treated controls, and 85-90% in comparison to 
the untreated controls. The functional mechanism of photosensitizers used in PCI is to become 
excited when exposed to light of the corresponding wavelength. This causes the formation of 
reactive oxygen species (ROS) [72], which causes the destruction of the cellular material close to 
the photosensitizers. The stress induced by the photosensitizers could activate signaling that affects 
MITF transcription. Shi et al showed recently that melanocytes respond to cellular stress by 
upregulating miR-25, a micro-RNA capable of negatively regulating MITF translation, supporting 
the observations in this project and providing a possible mechanism for these results [87].
LF2000 is a well described and widely used transfection reagent [88, 89]. It has been used in 
numerous scientific projects to facilitate the uptake of foreign substance into cells. From the results 
shown in this project, it is clear that use of LF2000 is preferable to PCI when transfecting SK-
Mel28, as it is less disruptive towards one of the key melanocyte genes. Of note, there are also other
available options for lipofection that have not been covered in this project that may be very useful 
for transfection of melanoma cell lines. Invitrogen, the producer of LF2000, is also offering 
Lipofectamine 3000, which their webpage describe as being less toxic than LF2000 while being 
more effective in numerous cell lines previously considered "hard to transfect". Another product 
described by Invitrogen is LF2000 RNAiMAX, which is a transfection agent optimized for siRNA 
delivery [90]. These agents could possibly provide even better siRNA knockdown than LF2000, but
this remains to be investigated.
During the MTS assay experiments, it was observed an increase in metabolic activity in cells 
transfected with LF2000 in comparison to the untreated controls. As LF2000 is toxic [99], the 
increase in 490 nm absorption could be due to the cells reacting to the possible cell stress/damage 
induced by LF2000.
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4.2 - Knock-down of MITF in SK-Mel28
siRNA-mediated knockdown of MITF and AP-2a were successfully carried out in the SK-Mel28 
cell line. In samples where MITF were knocked down showed, relative to controls, reduced levels 
of AP-2a mRNA and protein, increased levels of AP-2C mRNA, and increased levels of ERBB3 
mRNA and protein. In contrast, levels of ERBB2 mRNA, AKT protein and ERK protein were 
unaffected. However, levels of pAKT were found to be increased, while pERK levels were 
unaffected. These effects were consistent at both 24 and 72 h after transfection. A reduction in 
pAKT was observed in the samples transfected with AP-2a siRNA, but otherwise no other 
examined genes were found to be affected by AP-2a knockdown at either protein or mRNA level.
Cells with MITF-knockdown showed increased levels of pAKT, but unchanged levels of total AKT,
indicating higher AKT activity in cells transfected with MITF. It has been reported previously that 
ERBB3 is capable of affecting signaling in the PI3K/AKT-pathway [58, 68]. As we observed an 
increase in phosphorylation levels of AKT, rather than on the amounts of expressed AKT protein in 
the cells, these findings support existing studies where ERBB3 was found to be a modulator of the 
PI3K/AKT-pathway [58, 68]. Before any conclusions can be made it is necessary to validate that the
observed effect on PI3K/AKT-signaling is modulated by ERBB3 rather than an upstream gene 
targeted by MITF.
No changes in ERK and pERK levels were found in any western blot samples, even though 
increased activity in the ERBB3 has previously been shown to be able to affect signaling in the 
ERK/MAPK-pathway [64, 96]. According to in-house data, SK-Mel28 is homozygous for 
BRAF(V600E), which makes the ERK pathway constitutive activated [101]. This is a possible 
explanation for why no changes in the ERK or pERK levels were observed in samples where 
ERBB3 was affected. Further studies on the influence of ERBB3 and MITF on the ERK/MAPK-
signaling in a cell line without a BRAF(V600E)-mutation is therefore recommended.
The implication of these results is that MITF is a negative regulator of ERBB3-transcription, which 
gives it indirect control over proliferative and survival signal pathways. To further examine the role 
of MITF in pAKT regulation, it would be necessary to ensure that it is the altered ERBB3-levels, 
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rather than another protein regulated by MITF, that is responsible for the increased AKT activity. 
This could be done by examining cells after simultaneously knocking down MITF and ERBB3, 
alone and in combination.
Downregulation of MITF resulted in an increase in AP-2C mRNA expression. As described in the 
introduction chapter, AP-2C functions as a tumor suppressor [81], and increased levels of AP-2C 
should therefore inhibit tumor formation. At the same time, MITF silencing caused reduced levels 
of the tumor suppressor AP-2a and elevated levels of the proliferative signaling receptor ERBB3. 
Both of these effects promote tumor growth. The fact that MITF knockdown caused both the up- 
and down-regulation of different tumor suppressor genes, suggests that MITF a very complex gene 
and is capable of functioning as both an oncogene and tumor suppressor.
The results from the MTS assay showed an increase in metabolic activity in the MITF siRNA 
transfected samples compared to the controls. It is possible that the observed changes in metabolic 
activity in the MITF-transfected samples were due to increased AKT-signaling, which in turn could 
be mediated by the measured change in ERBB3-levels. However, ERBB3 is one out of many genes 
under the transcriptional control of MITF. It is therefore difficult to determine if the observed effect 
was due to elevated ERBB3-signaling without further experiments. Furthermore, the standard 
deviation between the parallels in the control samples were larger than that of the samples 
transfected with siRNA. This makes it difficult to determine if the observed increase in metabolic 
activity in the MITF transfected samples was significant.
As MTS assays are used for measuring metabolic activity in cells, it may give an indication of the 
cell proliferation rate, as wells with higher cell counts are likely to have higher levels of metabolic 
activity. However, this does not directly confirm whether proliferation is actually affected, or if any 
changes in metabolic activity are for other reasons. The results will therefore have to be verified 
further. This can be done by cell density measurements or by use of a survivability assay, both 
alternative methods suited for of measuring cell proliferation. One such technique, IncuCyte, 
involves analyzing and comparing differences in cell confluency [91], which may offer a better 
measurement for proliferation and survival than the MTS assay.
MITF is a complex gene, which exerts influence on a large variety of genes, and where different 
expression levels of the gene are associated with different phenotypes in melanocytes [45]. It's 
difficult to predict the effects of targeting MITF therapeutically; in fact, some studies have 
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previously concluded that MITF is not a druggable target [102] and that it is likely more productive 
to examine its upstream modulators as therapeutic targets [45]. The results obtained in this study are
consistent with these claims, as MITF silencing resulted in increased metabolic activity and AKT-
signaling in SK-Mel28. Due to the limited scope of the project, however, no conclusions can be 
drawn on the viability of MITF as a therapeutic target from these data alone. On the other hand, the 
results of the study do show a correlation between MITF expression and AP-2a, AP-2C and 
ERBB3.
Knocking down MITF in this study resulted in increased pAKT, and an upregulation of metabolic 
activity in the SKmel-28 cell line. SKmel-28 is a metastatic cell line that has an amplification of the
MITF gene and high levels of MITF expression, in addition to having a non-functional p53-gene 
and being homozygous for BRAF(V600E). (in-house data) It would be very interesting to 
investigate the response of MITF transfections attempted in this study in other cell lines. 
Considering how different levels of MITF expression is reported to be associated with different 
melanoma cell phenotypes, [45] the results of MITF silencing in melanoma cell lines with different 
levels of MITF expression could yield different results than those obtained here. Melanoma cell 
lines in a different disease stage could also react differently to MITF knockdown compared to 
metastatic cell lines. MITF silencing in SK-Mel28 did not affect the protein levels of ERK or pERK
in this study. Investigating the effects of MITF silencing in a cell line that is not homozygous for 
BRAF(V600E) is recommended.
4.3 - Knock-down of AP-2a in SK-Mel28
AP-2a knockdown was not observed to affect the metabolic activity, as measured by the MTS 
assays. However, MITF knockdown which caused AP-2a downregulation was observed to  increase 
the metabolic activity. AP-2a functions as a tumor suppressor gene and low levels of the gene is 
associated with disease progression in cancer cells [54]. One of AP-2a's functions is to cooperate 
with p53 to induce p21 expression in the cells, which again binds to the cyclin-dependent kinase 2 
(CDK2). The CDK2-p21-complex prevents cell cycle progression past the G1-phase [92]. The SK-
Mel28 cell line has a nonfunctional p53 gene, (in-house data) shutting down p53-p21-signaling 
independent of AP-2a. This could be a possible explanation for why reduced levels of AP-2a did not
cause any changes in metabolic activity. Previous studies have also shown a correlation between 
ERBB2-overexpression and high levels of AP-2a in breast cancer [100]: ERBB2 has been found to 
affect the MAPK/ERK-pathway, and may give AP-2a indirect influence over ERK-signaling in cell 
lines that contain wild type BRAF. However, in this project, we did not detect any effect upon 
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ERBB2 mRNA when knocking down AP-2a.
Knock-down of AP-2a resulted in reduced pAKT-levels compared to the control samples. This was 
less apparent in the 72 h samples compared to the 24 h samples. As AP-2a is thought to function as 
a tumor suppressor, it was surprising to detect that lower AP-2a levels lead to a decrease in pAKT 
levels. It was also interesting to see MITF knockdown leading to AP-2a downregulation, yet MITF 
knockdown caused increased AKT-signaling rather than reduced. Sumigama et al [86] increased 
AP-2a levels in the SKOV3 ovarian cancer cell line and observed reduced levels of pAKT and 
pERBB2 as a consequence. Other studies have hinted that AP-2 proteins can function both as an 
oncogene as well as a tumor suppressor [97], and it is possible that AP-2a has a different function in
melanoma compared to ovarian cancer. Sumigama et al also specifies that the SKOV3 cell line has 
a low initial level of AP-2a. The AP-2a levels in SK-Mel28 in comparison to other cell lines is at the
present moment not known. As since the cell line has a high expression level of MITF, a gene that 
upregulates AP-2a, it is a possibility that this would cause an increase in AP-2a expression. This has
to be verified, however. It is also known that cancer cells can have different expression profiles in 
regards to which AP-2a isoforms that are expressed in SK-Mel28. While the 1a isoform is the most 
highly expressed, it has been observed that breast cancer cell lines can have increased levels of the 
1b and 1c isoforms [85]. Berlato et al shows the 1a isoform is reported as the only subunit capable 
of acting as a direct repressor, while the 1b and 1c isoforms are both capable of transactivating the 
ERBB2-promoter [85]. As ERBB2 is capable of affecting the PI3K/AKT-pathway, knocking down 
AP-2a could influence PI3K/AKT-signaling indirectly by upregulating ERBB2 through the 1b and 
1c. However, no changes in ERBB2 mRNA-levels were detected in cells transfected with AP-2a 
siRNA (figure 9b). Further investigation on the role of AP-2a in melanoma cells is recommended to 
verify the validity of the results obtained in this project.
4.4 - Future perspectives
The results obtained in this study could indicate that ERBB3 is capable of affecting the AKT-
pathway. Other studies have found similar results [96], and efforts to target ERBB3 therapeutically 
has been made [93-95]. As a surface receptor, a likely method for targeting ERBB3 would be 
antibodies. It has been attempted to create therapeutic antibodies that block ERBB2-ERBB3-
dimerization, which is one possible method of action against ERBB3 [98]. MITF, however, may not
be suited as a drug target, and needs further examination. Furthermore, the results obtained in this 
study will have to be verified to ensure their relevance. One way to accomplish this is to carry out 
MITF- and AP-2a silencing in other cell lines, particularly ones that are not BRAF(V600E)-
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homozygous, or in a metastatic phase. The results of the MTS assay are also not enough to draw 
any conclusions, and it is recommended to supplement these results with data obtained with other 
techniques. Furthermore, the effects ERBB3 has on cell proliferation and survival needs to be 
further verified: while MITF-transfected cells had increased levels of both ERBB3 and pAKT, it is 
necessary to look at ERBB3 alone. This project has not examined how MITF levels affect the 
invasiveness of melanoma cell lines, which could be done through matrigel analysis [103]. 
Examining how MITF silencing affects melanocytes in vivo is also a way to provide useful research
data on MITF. The results obtained on AP-2a also need to be further verified, in order to examine 
the role of the gene in melanoma.
4.5 - Conclusions
In conclusion, the testing of two different transfection methods on melanoma cells showed that 
Lipofectamine 2000 was overall a preferred method to PCI in SK-Mel28: both the photosensitizer 
and the 435 nm light treatment used in PCI significantly affected the expression levels of MITF, the 
master regulator of melanocyte function. Furthermore, we observed a correlation between the levels
of MITF in SK-Mel28, and the levels of AP-2a, ERBB3 and AP-2C in these cells. Additionally, 
MITF knockdown positively affected AKT-signaling. None of the silenced genes affected the levels 
of ERK or pERK, though that is likely due to the cell line used being BRAF(V600E)-homozygous, 
which makes the pathway constitutively active and thus largely unaffected by MAPK upstream 
signaling. It is possible that the effect on AKT signaling is a consequence of the increased level of 
ERBB3 after MITF knockdown. However, this has to be further investiagted. AP-2a silencing 
unexpectedly reduced signaling in the PI3K/AKT-pathway. At the moment we have no explanation 
for this effect, and further studies have to be done to reveal the role of AP-2a upon the PI3K/AKT-
pathway.
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Appendix
Appendix A - Buffers and solutions used in the project
Table A1: Complete growth medium supplements
Supplement Concentration Per 500 ml RPMI 1640
Fetal bovine serum 10% 50 ml
glutaMAX 2 mM 5.5 ml of 200 mM stock
Table A2: Contents of prepared protein samples for gel electrophoresis
Compound Volume (ul)
NuPAGE LDS sample buffer (4X) 2,5
NuPAGE Reducing Agent (10x) 1
Protein sample X
ddH2O 6,5 - X
Total volume 10
Table A3: Contents of TBS-T 0.1% wash buffer (Tris-buffered saline /w 0.1% Tween 20)
Compound Volume (ml)
5M NaCl 27,4
1M Tris-HCl pH 7,5 20
20% Tween 20 5
ddH2O Up to 1000
63
Table A4: Contents of lysis buffer for protein harvesting
Compound Concentration Volume (ml)
NaCl 150 mM 1,5
Tris pH 7.5 50 mM 5
Nonidet P40 0.10% 0,05 (50 ul)
ddH2O ------ to 50 ml
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Appendix B -Antibody conditions for western blotting
Primary Ab Size 
(kDa)
Blocking Primary Ab 
dilution
Secondary Ab 
+ dilution
Buffer for Ab 
dilution
Histone H3 17 5% dry milk 1:3000 Rabbit, 1:8000 5% dry milk in 
TBS-T
MITF 50-54 5% BSA 1:2000 Rabbit, 1:5000 5% BSA in 
TBS-T
AP-2a 48 5% BSA 1:3000 Rabbit, 1:8000 5% BSA in 
TBS-T
ERBB3 185 5% BSA 1:1000 Rabbit,1:5000 5% BSA in 
TBS-T
AKT 60 5% BSA 1:1000 Rabbit, 1:5000 5% BSA in 
TBS-T
pAKT XP 60 5% BSA 1:2000 Rabbit, 1:6000 5% BSA in 
TBS-T
ERK 1/2 44/42 5% BSA 1:3000 Rabbit, 1:7000 5% BSA in 
TBS-T
pERK 1/2 44/42 5% BSA 1:2000 Rabbit, 1:7000 5% BSA in 
TBS-T
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Appendix C - Real time PCR data
Table C1: Primer sequences for qPCR
Gene Forward primer (5'-3') Reverse primer (3'-5')
TBP GCC-CGA-AAC-GCC-GAA-
TAT
CGT-GGC-TCT-CTT-ATC-
CTC-ATG-A
RPLPO TCG-AAC-ACC-TGC-TGG-
ATG-AC
CGC-TGC-TGA-ACA-TGC-
TCA-AC
MITF-m CAT-TGT-TAT-GCT-GGA-
AAT-GCT-AGA
GCT-AAA-GTG-GTA-GAA-
AGG-TAC-TGC
AP-2a AGG-GGA-GAT-CGG-TCC-
TGA
ACA-TGC-TCC-TGG-CTA-
CAA-AAC
ERBB3 CTG-ATC-ACC-GGC-CTC-
AAT
GGA-AGA-CAT-TGA-GCT-
TCT-CTG-G
AP-2C GGG-GCT-GTA-GAG-GTG-
CTG
CGA-AGA-GGA-CTG-CGA-
GGA
ERBB2 GGG-AAA-CCT-GGA-ACT-
CAC-CT
CCC-TGC-ACC-TCC-TGG-
ATA
MEK1 TTC-TAC-AGC-GAT-GGC-
GAG-AT
TCC-AGC-TTT-CTT-CAG-
GAC-TTG
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Appendix D - MTS data
Figure D1: MTS abs values in absolute values
Figure D1: Absolute values of the 490 nm absorption observed in the MTS assay. D1a) shows raw values, D1b) shows 
values compared to the untreated sample.
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Appendix E - Western blot supplementary data
Table E1: Standard curve of reference for the calculation of protein concentrations
Reference protein, μg Protein standard solution, μl ddH2O, μl
0 0 10
1 0,66 9,33
2 1,32 8,68
3 1,98 8,02
4 2,34 7,66
5 3,00 7,0
The protein standard stock solution used in this project was BioRad Protein Standard, which has a 
concentration of 1,52 μg/μl.
Figure E1: Example of a standard curve used for calculating protein concentration
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Appendix F - qPCR-data
Measurements of relative expression in each individual sample, as well as the mean cycle threshold 
of each gene.
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